Key result
Hypertrophic cardiomyopathy is now recognized as the most common monogenic cardiovascular disease with an estimated prevalence of 0.2% and an improved annual mortality rate of less than 1%.
This review provides an updated overview of hypertrophic cardiomyopathy, highlighting its higher-than-previously-thought prevalence, improved prognosis, and the evolving roles of medical and septal reduction therapies.
Answers are grounded in this paper and cite their sources.
May prompt broader HCM screening in practice; leaves open optimal therapy selection in diverse populations.
PrĂĄce shrnuje nÄkterĂŠ novĂŠ poznatky tĂ˝kajĂcĂ se hypertrofickĂ˝ch kardiomyopatiĂ. ZabĂ˝vĂĄ se jejich souÄasnou definicĂ, genetickĂ˝mi nĂĄlezy a vztahem k fenotypu onemocnÄnĂ, dĂĄle otĂĄzkami vĂ˝skytu, prognĂłzy onemocnÄnĂ. DiskutovĂĄny jsou i souÄasnĂŠ nĂĄzory na lĂŠÄbu, pĹedevĹĄĂm s ohledem na provĂĄdÄnĂ perkutĂĄnnĂch septĂĄlnĂch ablacĂ a myektomiĂ u tÄĹžce symptomatickĂ˝ch, obstrukÄnĂch forem.
No takes yet. Share an insight, caveat, or question.
Gregor et al. (2012) conducted a review in Hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy management was evaluated. Hypertrophic cardiomyopathy is now recognized as the most common monogenic cardiovascular disease with an estimated prevalence of 0.2% and an improved annual mortality rate of less than 1%.
Synapse has enriched 10 related papers. Consider them for comparative context: